CoChat

Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening

Sarafoglou, K, Lorentz, C P, Otten, N, Oetting, W S, Grebe, S K G · 2012 · Clinical Genetics
Cited by 16

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Sarafoglou K, Lorentz CP, Otten N, Oetting WS, Grebe SKG. Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening. Newborn screening (NBS) identifies the majority of classical [salt‐wasting (SW) and simple‐virilizing (SV)] cases of congenital adrenal hyperplasia (CAH) due to 21 α‐hydroxylase (21 α‐OHase) during the first days of life. Diagnosis of classical CAH is confirmed by follow‐up serum 17‐hydroxyprogesterone and/or the adrenocorticotropin stimulation test; however, neither test definitively distinguishes between the classical subtypes. After confirmation, all newborns are started on hydrocortisone (glucocorticoid) and fludrocortisone (mineralocorticoid) treatment. While initiating fludrocortisone treatment in classical CAH patients, independent of subtype and before SW signs or symptoms occur, prevents a life‐threatening SW crisis, it may later complicate distinguishing between the classical subtypes. Genotype–phenotype correlations in 21 α‐OHase deficiency are excellent; however, molecular testing is not a regular part of the diagnostic workup. Molecular testing on 39 patients (25 identified by NBS) with an already established diagnosis of CAH identified 11 SW patients (8 identified by NBS) whose mutations suggested further biochemical and clinical reassessment of their subtype. Overall, SW accounted for 57.6% of our classical CAH patients, below the generally accepted figure that >75% of classical CAH are comprised of the SW form. In the era of NBS, molecular testing is a valuable supplemental tool identifying patients who may benefit from reassessment of their salt‐retaining ability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1399-0004.2011.01694.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 16

Metadata

Authors
Sarafoglou, K., Lorentz, C. P., Otten, N., Oetting, W. S., & Grebe, S. K. G.
Venue
Clinical Genetics
Publisher
Wiley
Published
2011-06-03
Volume
82
Issue
1
Pages
64-70
ISSN
  • 0009-9163 (ISSN-L)
  • 1399-0004
OpenAlex
W2101943800
Cited by
16
References
16
FWCI
0.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening. https://app.cochat.ai/papers/10.1111/j.1399-0004.2011.01694.x
The paper
Sarafoglou, K., Lorentz, C. P., Otten, N., Oetting, W. S., & Grebe, S. K. G. (2012). Molecular testing in congenital adrenal hyperplasia due to 21 α‐hydroxylase deficiency in the era of newborn screening. Clinical Genetics. https://doi.org/10.1111/j.1399-0004.2011.01694.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.